Nasus Pharma CEO discloses initial share and option stake

Nasus Pharma Ltd director and CEO Dan Benjamin Teleman filed an initial statement of ownership.

Accepted by SEC EDGAR 03/27/2026 - 08:56 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Nasus Pharma Ltd director and CEO Dan Benjamin Teleman filed an initial statement of ownership. He holds options over 318,855 Ordinary Shares, granted at an exercise price of $6.046 per share, expiring on January 7, 2035, with 132,845 options already vested as of March 18, 2026. He also directly owns 6,246 Ordinary Shares.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Teleman Dan Benjamin

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Holding	Share option (right to buy)	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Share option (right to buy) — 318,856 contracts (Direct); Ordinary Shares — 6,246 shares (Direct)

Footnotes (1)

1. F1. Options to purchase 318,856 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on January 16, 2025,with 33.33% of the total grant vesting on January 7, 2026, and the remaining 66.67% vesting in equal quarterly installments of 8.3338% thereafter. As of March 18, 2026, 318,855 options remain outstanding, of which 132,845 are vested and exercisable, at an exercise price of $6.046 per share, expiring January 7, 2035.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Nasus Pharma (NSRX) CEO Dan Teleman report on this Form 3?

Dan Teleman reports his initial ownership in Nasus Pharma. He holds options over 318,855 Ordinary Shares at $6.046 per share plus 6,246 Ordinary Shares directly, establishing his baseline equity position as of March 18, 2026.

How many Nasus Pharma (NSRX) options does the CEO have and at what price?

The CEO holds options to purchase 318,855 Ordinary Shares of Nasus Pharma. These options have an exercise price of $6.046 per share and expire on January 7, 2035, defining a long-term incentive position tied to the company’s share price performance.

How many Nasus Pharma (NSRX) options are vested for the CEO as of March 18, 2026?

As of March 18, 2026, 132,845 of Dan Teleman’s options in Nasus Pharma are vested and exercisable. The remaining options continue to vest in equal quarterly installments, following the original grant schedule described in the footnote.

What is the vesting schedule of the Nasus Pharma (NSRX) CEO’s option grant?

The option grant vests 33.33% on January 7, 2026, with the remaining 66.67% vesting in equal quarterly installments of 8.3338%. This schedule gradually increases the CEO’s exercisable options over time, aligning compensation with ongoing service.

What direct share ownership does the Nasus Pharma (NSRX) CEO report?

Dan Teleman reports direct ownership of 6,246 Ordinary Shares of Nasus Pharma. These shares are separate from his options and represent his current, fully owned equity stake in the company as of the reported date.

Does this Nasus Pharma (NSRX) Form 3 show any recent insider buying or selling?

No new purchases or sales are indicated; it is an initial ownership report. The filing lists existing option and share holdings, without showing recent open-market buys, sales, or option exercises by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Teleman Dan Benjamin

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	6,246	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)(1)	01/07/2026	01/07/2035	Ordinary Shares	318,856	$6.05	D

Explanation of Responses:

1. Options to purchase 318,856 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on January 16, 2025,with 33.33% of the total grant vesting on January 7, 2026, and the remaining 66.67% vesting in equal quarterly installments of 8.3338% thereafter. As of March 18, 2026, 318,855 options remain outstanding, of which 132,845 are vested and exercisable, at an exercise price of $6.046 per share, expiring January 7, 2035.

	/s/ Dan Benjamin Teleman	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)